R&D News | pharmaphorum

News

Novartis drops geographic atrophy gene therapy

Novartis has confirmed it will discontinue development of a gene therapy for sight-robbing disease geographic atrophy (GA) two years after acquiring its UK-based developer

News

WCLC: Chemo adds efficacy and side effects to AZ's Tagrisso

Giving AstraZeneca's EGFR tyrosine kinase inhibitor (TKI) inhibitor Tagrisso in combination with chemotherapy to patients with EGFR-mutated non-small cell lung cancer (NSC

News

First-in-class BMS drug raises lung fibrosis hopes

Bristol-Myers Squibb has proof-of-concept data for an experimental drug for fibrotic diseases that could open up a new avenue for treatment.

News

WCLC: Amgen eyes first-line use for KRAS drug Lumakras

Amgen is facing a slowdown in uptake of its first-to-market KRAS inhibitor Lumakras as a second-line therapy for KRAS-mutated non-small cell lung cancer (NSCLC), so is und

News

AZ's Alexion inks wide-ranging AI agreement with Verge

AstraZeneca has made a sizeable play in applying artificial intelligence to drug discovery in its rare disease unit Alexion, partnering with Verge Genomics in a deal that

News

WCLC: Data back first-line use of Gilead, AZ/Daiichi TROP2s

AstraZeneca/Daiichi Sankyo and Gilead Sciences have reported preliminary results of studies that suggest their TROP2-targeted antibody-drug conjugates (ADCs) could have a

Novartis drops geographic atrophy gene therapy

WCLC: Chemo adds efficacy and side effects to AZ's Tagrisso

First-in-class BMS drug raises lung fibrosis hopes

WCLC: Amgen eyes first-line use for KRAS drug Lumakras

AZ's Alexion inks wide-ranging AI agreement with Verge

WCLC: Data back first-line use of Gilead, AZ/Daiichi TROP2s

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

How to meet your physicians where they are online

News

Editor's Picks